Acute neonatal effects following prenatal venlafaxine exposure
Ugeskrift for Læger · 2026-10-19 · 1-4
DOI: 10.61409/v03260181 ↗Abstract
Venlafaxine is a serotonin-noradrenaline reuptake inhibitor. Intrauterine exposure may cause neonatal withdrawal symptoms known as poor neonatal adaptation syndrome (PNAS). In this case report, we present a term newborn with respiratory distress and neurological hyperexcitability after birth following maternal venlafaxine treatment. Evaluation excluded infectious and neurological causes, and symptoms resolved in days. PNAS should be considered despite early symptoms. Regional variation in observation practices may affect recognition of PNAS, underscoring the need for awareness of the condition.
EUVIMED